Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Lentiviral Gene Therapy with Autologous Hematopoietic Stem Cells
2013-002245-11Phase 2Active
- Sponsor
- bluebird bio, Inc.
- Start
- May 2014
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LentiGlobin HPV569 in sickle cell disease (SCD) and beta thalassemia, sponsored by bluebird bio, Inc. Primary endpoints: Long-term safety monitoring and Long-term efficacy monitoring. Started May 2014; status: active.
02
Drugs
LentiGlobin HPV569
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on 2013-002245-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002245-11.